

Global Hypertensive Heart Disease Drug Market Research Report 2023

<https://marketpublishers.com/r/G69735A54CC9EN.html>

Date: October 2023

Pages: 138

Price: US\$ 2,900.00 (Single User License)

ID: G69735A54CC9EN

Abstracts

This report aims to provide a comprehensive presentation of the global market for Hypertensive Heart Disease Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hypertensive Heart Disease Drug.

The Hypertensive Heart Disease Drug market size, estimations, and forecasts are provided in terms of and revenue (\$ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Hypertensive Heart Disease Drug market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Hypertensive Heart Disease Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

By Company

Abbott Laboratories

AstraZeneca PLC

Actelion Pharmaceuticals Ltd.

Boehringer Ingelheim International GmbH

Bayer AG

Eiger Biopharmaceuticals, Inc.

Daiichi Sankyo Co., Ltd.

Gilead Sciences, Inc.

GlaxoSmithKline PLC

F. Hoffmann-La Roche Ltd.

Johnson & Johnson Services, Inc.

Lupin Pharmaceuticals, 13. Merck KGaA

Novartis AG

Pfizer Inc.

Sanofi SA

Sun Pharmaceutical Industries Ltd.

Takeda Pharmaceutical Co. Ltd.

United Therapeutics Corp.

Northern Therapeutics Inc.

Segment by Type

Calcium Channel Blockers

Diuretics

Beta Blockers

ACE Inhibitors

Potassium Replacements

Segment by Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hypertensive Heart Disease Drug companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.

Contents

1 REPORT OVERVIEW

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Hypertensive Heart Disease Drug Market Size Growth Rate by Type:
2018 VS 2022 VS 2029

1.2.2 Calcium Channel Blockers

1.2.3 Diuretics

1.2.4 Beta Blockers

1.2.5 ACE Inhibitors

1.2.6 Potassium Replacements

1.3 Market by Application

1.3.1 Global Hypertensive Heart Disease Drug Market Growth by Application: 2018 VS
2022 VS 2029

1.3.2 Hospital Pharmacies

1.3.3 Retail Pharmacies

1.3.4 Online Pharmacies

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Hypertensive Heart Disease Drug Market Perspective (2018-2029)

2.2 Hypertensive Heart Disease Drug Growth Trends by Region

2.2.1 Global Hypertensive Heart Disease Drug Market Size by Region: 2018 VS 2022
VS 2029

2.2.2 Hypertensive Heart Disease Drug Historic Market Size by Region (2018-2023)

2.2.3 Hypertensive Heart Disease Drug Forecasted Market Size by Region
(2024-2029)

2.3 Hypertensive Heart Disease Drug Market Dynamics

2.3.1 Hypertensive Heart Disease Drug Industry Trends

2.3.2 Hypertensive Heart Disease Drug Market Drivers

2.3.3 Hypertensive Heart Disease Drug Market Challenges

2.3.4 Hypertensive Heart Disease Drug Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Hypertensive Heart Disease Drug Players by Revenue

3.1.1 Global Top Hypertensive Heart Disease Drug Players by Revenue (2018-2023)

3.1.2 Global Hypertensive Heart Disease Drug Revenue Market Share by Players (2018-2023)

3.2 Global Hypertensive Heart Disease Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Hypertensive Heart Disease Drug Revenue

3.4 Global Hypertensive Heart Disease Drug Market Concentration Ratio

3.4.1 Global Hypertensive Heart Disease Drug Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Hypertensive Heart Disease Drug Revenue in 2022

3.5 Hypertensive Heart Disease Drug Key Players Head office and Area Served

3.6 Key Players Hypertensive Heart Disease Drug Product Solution and Service

3.7 Date of Enter into Hypertensive Heart Disease Drug Market

3.8 Mergers & Acquisitions, Expansion Plans

4 HYPERTENSIVE HEART DISEASE DRUG BREAKDOWN DATA BY TYPE

4.1 Global Hypertensive Heart Disease Drug Historic Market Size by Type (2018-2023)

4.2 Global Hypertensive Heart Disease Drug Forecasted Market Size by Type (2024-2029)

5 HYPERTENSIVE HEART DISEASE DRUG BREAKDOWN DATA BY APPLICATION

5.1 Global Hypertensive Heart Disease Drug Historic Market Size by Application (2018-2023)

5.2 Global Hypertensive Heart Disease Drug Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Hypertensive Heart Disease Drug Market Size (2018-2029)

6.2 North America Hypertensive Heart Disease Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Hypertensive Heart Disease Drug Market Size by Country (2018-2023)

6.4 North America Hypertensive Heart Disease Drug Market Size by Country

(2024-2029)

6.5 United States

6.6 Canada

7 EUROPE

7.1 Europe Hypertensive Heart Disease Drug Market Size (2018-2029)

7.2 Europe Hypertensive Heart Disease Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Hypertensive Heart Disease Drug Market Size by Country (2018-2023)

7.4 Europe Hypertensive Heart Disease Drug Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 ASIA-PACIFIC

8.1 Asia-Pacific Hypertensive Heart Disease Drug Market Size (2018-2029)

8.2 Asia-Pacific Hypertensive Heart Disease Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Hypertensive Heart Disease Drug Market Size by Region (2018-2023)

8.4 Asia-Pacific Hypertensive Heart Disease Drug Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 LATIN AMERICA

9.1 Latin America Hypertensive Heart Disease Drug Market Size (2018-2029)

9.2 Latin America Hypertensive Heart Disease Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Hypertensive Heart Disease Drug Market Size by Country (2018-2023)

9.4 Latin America Hypertensive Heart Disease Drug Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Hypertensive Heart Disease Drug Market Size (2018-2029)

10.2 Middle East & Africa Hypertensive Heart Disease Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Hypertensive Heart Disease Drug Market Size by Country (2018-2023)

10.4 Middle East & Africa Hypertensive Heart Disease Drug Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 KEY PLAYERS PROFILES

11.1 Abbott Laboratories

11.1.1 Abbott Laboratories Company Detail

11.1.2 Abbott Laboratories Business Overview

11.1.3 Abbott Laboratories Hypertensive Heart Disease Drug Introduction

11.1.4 Abbott Laboratories Revenue in Hypertensive Heart Disease Drug Business (2018-2023)

11.1.5 Abbott Laboratories Recent Development

11.2 AstraZeneca PLC

11.2.1 AstraZeneca PLC Company Detail

11.2.2 AstraZeneca PLC Business Overview

11.2.3 AstraZeneca PLC Hypertensive Heart Disease Drug Introduction

11.2.4 AstraZeneca PLC Revenue in Hypertensive Heart Disease Drug Business (2018-2023)

11.2.5 AstraZeneca PLC Recent Development

11.3 Actelion Pharmaceuticals Ltd.

11.3.1 Actelion Pharmaceuticals Ltd. Company Detail

11.3.2 Actelion Pharmaceuticals Ltd. Business Overview

11.3.3 Actelion Pharmaceuticals Ltd. Hypertensive Heart Disease Drug Introduction

11.3.4 Actelion Pharmaceuticals Ltd. Revenue in Hypertensive Heart Disease Drug

Business (2018-2023)

11.3.5 Actelion Pharmaceuticals Ltd. Recent Development

11.4 Boehringer Ingelheim International GmbH

11.4.1 Boehringer Ingelheim International GmbH Company Detail

11.4.2 Boehringer Ingelheim International GmbH Business Overview

11.4.3 Boehringer Ingelheim International GmbH Hypertensive Heart Disease Drug Introduction

11.4.4 Boehringer Ingelheim International GmbH Revenue in Hypertensive Heart Disease Drug Business (2018-2023)

11.4.5 Boehringer Ingelheim International GmbH Recent Development

11.5 Bayer AG

11.5.1 Bayer AG Company Detail

11.5.2 Bayer AG Business Overview

11.5.3 Bayer AG Hypertensive Heart Disease Drug Introduction

11.5.4 Bayer AG Revenue in Hypertensive Heart Disease Drug Business (2018-2023)

11.5.5 Bayer AG Recent Development

11.6 Eiger Biopharmaceuticals, Inc.

11.6.1 Eiger Biopharmaceuticals, Inc. Company Detail

11.6.2 Eiger Biopharmaceuticals, Inc. Business Overview

11.6.3 Eiger Biopharmaceuticals, Inc. Hypertensive Heart Disease Drug Introduction

11.6.4 Eiger Biopharmaceuticals, Inc. Revenue in Hypertensive Heart Disease Drug Business (2018-2023)

11.6.5 Eiger Biopharmaceuticals, Inc. Recent Development

11.7 Daiichi Sankyo Co., Ltd.

11.7.1 Daiichi Sankyo Co., Ltd. Company Detail

11.7.2 Daiichi Sankyo Co., Ltd. Business Overview

11.7.3 Daiichi Sankyo Co., Ltd. Hypertensive Heart Disease Drug Introduction

11.7.4 Daiichi Sankyo Co., Ltd. Revenue in Hypertensive Heart Disease Drug Business (2018-2023)

11.7.5 Daiichi Sankyo Co., Ltd. Recent Development

11.8 Gilead Sciences, Inc.

11.8.1 Gilead Sciences, Inc. Company Detail

11.8.2 Gilead Sciences, Inc. Business Overview

11.8.3 Gilead Sciences, Inc. Hypertensive Heart Disease Drug Introduction

11.8.4 Gilead Sciences, Inc. Revenue in Hypertensive Heart Disease Drug Business (2018-2023)

11.8.5 Gilead Sciences, Inc. Recent Development

11.9 GlaxoSmithKline PLC

11.9.1 GlaxoSmithKline PLC Company Detail

- 11.9.2 GlaxoSmithKline PLC Business Overview
- 11.9.3 GlaxoSmithKline PLC Hypertensive Heart Disease Drug Introduction
- 11.9.4 GlaxoSmithKline PLC Revenue in Hypertensive Heart Disease Drug Business (2018-2023)
- 11.9.5 GlaxoSmithKline PLC Recent Development
- 11.10 F. Hoffmann-La Roche Ltd.
 - 11.10.1 F. Hoffmann-La Roche Ltd. Company Detail
 - 11.10.2 F. Hoffmann-La Roche Ltd. Business Overview
 - 11.10.3 F. Hoffmann-La Roche Ltd. Hypertensive Heart Disease Drug Introduction
 - 11.10.4 F. Hoffmann-La Roche Ltd. Revenue in Hypertensive Heart Disease Drug Business (2018-2023)
 - 11.10.5 F. Hoffmann-La Roche Ltd. Recent Development
- 11.11 Johnson & Johnson Services, Inc.
 - 11.11.1 Johnson & Johnson Services, Inc. Company Detail
 - 11.11.2 Johnson & Johnson Services, Inc. Business Overview
 - 11.11.3 Johnson & Johnson Services, Inc. Hypertensive Heart Disease Drug Introduction
 - 11.11.4 Johnson & Johnson Services, Inc. Revenue in Hypertensive Heart Disease Drug Business (2018-2023)
 - 11.11.5 Johnson & Johnson Services, Inc. Recent Development
- 11.12 Lupin Pharmaceuticals, 13. Merck KGaA
 - 11.12.1 Lupin Pharmaceuticals, 13. Merck KGaA Company Detail
 - 11.12.2 Lupin Pharmaceuticals, 13. Merck KGaA Business Overview
 - 11.12.3 Lupin Pharmaceuticals, 13. Merck KGaA Hypertensive Heart Disease Drug Introduction
 - 11.12.4 Lupin Pharmaceuticals, 13. Merck KGaA Revenue in Hypertensive Heart Disease Drug Business (2018-2023)
 - 11.12.5 Lupin Pharmaceuticals, 13. Merck KGaA Recent Development
- 11.13 Novartis AG
 - 11.13.1 Novartis AG Company Detail
 - 11.13.2 Novartis AG Business Overview
 - 11.13.3 Novartis AG Hypertensive Heart Disease Drug Introduction
 - 11.13.4 Novartis AG Revenue in Hypertensive Heart Disease Drug Business (2018-2023)
 - 11.13.5 Novartis AG Recent Development
- 11.14 Pfizer Inc.
 - 11.14.1 Pfizer Inc. Company Detail
 - 11.14.2 Pfizer Inc. Business Overview
 - 11.14.3 Pfizer Inc. Hypertensive Heart Disease Drug Introduction

- 11.14.4 Pfizer Inc. Revenue in Hypertensive Heart Disease Drug Business (2018-2023)
- 11.14.5 Pfizer Inc. Recent Development
- 11.15 Sanofi SA
 - 11.15.1 Sanofi SA Company Detail
 - 11.15.2 Sanofi SA Business Overview
 - 11.15.3 Sanofi SA Hypertensive Heart Disease Drug Introduction
 - 11.15.4 Sanofi SA Revenue in Hypertensive Heart Disease Drug Business (2018-2023)
 - 11.15.5 Sanofi SA Recent Development
- 11.16 Sun Pharmaceutical Industries Ltd.
 - 11.16.1 Sun Pharmaceutical Industries Ltd. Company Detail
 - 11.16.2 Sun Pharmaceutical Industries Ltd. Business Overview
 - 11.16.3 Sun Pharmaceutical Industries Ltd. Hypertensive Heart Disease Drug Introduction
 - 11.16.4 Sun Pharmaceutical Industries Ltd. Revenue in Hypertensive Heart Disease Drug Business (2018-2023)
 - 11.16.5 Sun Pharmaceutical Industries Ltd. Recent Development
- 11.17 Takeda Pharmaceutical Co. Ltd.
 - 11.17.1 Takeda Pharmaceutical Co. Ltd. Company Detail
 - 11.17.2 Takeda Pharmaceutical Co. Ltd. Business Overview
 - 11.17.3 Takeda Pharmaceutical Co. Ltd. Hypertensive Heart Disease Drug Introduction
 - 11.17.4 Takeda Pharmaceutical Co. Ltd. Revenue in Hypertensive Heart Disease Drug Business (2018-2023)
 - 11.17.5 Takeda Pharmaceutical Co. Ltd. Recent Development
- 11.18 United Therapeutics Corp.
 - 11.18.1 United Therapeutics Corp. Company Detail
 - 11.18.2 United Therapeutics Corp. Business Overview
 - 11.18.3 United Therapeutics Corp. Hypertensive Heart Disease Drug Introduction
 - 11.18.4 United Therapeutics Corp. Revenue in Hypertensive Heart Disease Drug Business (2018-2023)
 - 11.18.5 United Therapeutics Corp. Recent Development
- 11.19 Northern Therapeutics Inc.
 - 11.19.1 Northern Therapeutics Inc. Company Detail
 - 11.19.2 Northern Therapeutics Inc. Business Overview
 - 11.19.3 Northern Therapeutics Inc. Hypertensive Heart Disease Drug Introduction
 - 11.19.4 Northern Therapeutics Inc. Revenue in Hypertensive Heart Disease Drug Business (2018-2023)

11.19.5 Northern Therapeutics Inc. Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS

13 APPENDIX

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Global Hypertensive Heart Disease Drug Market Size Growth Rate by Type (US\$ Million): 2018 VS 2022 VS 2029

Table 2. Key Players of Calcium Channel Blockers

Table 3. Key Players of Diuretics

Table 4. Key Players of Beta Blockers

Table 5. Key Players of ACE Inhibitors

Table 6. Key Players of Potassium Replacements

Table 7. Global Hypertensive Heart Disease Drug Market Size Growth by Application (US\$ Million): 2018 VS 2022 VS 2029

Table 8. Global Hypertensive Heart Disease Drug Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 9. Global Hypertensive Heart Disease Drug Market Size by Region (2018-2023) & (US\$ Million)

Table 10. Global Hypertensive Heart Disease Drug Market Share by Region (2018-2023)

Table 11. Global Hypertensive Heart Disease Drug Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 12. Global Hypertensive Heart Disease Drug Market Share by Region (2024-2029)

Table 13. Hypertensive Heart Disease Drug Market Trends

Table 14. Hypertensive Heart Disease Drug Market Drivers

Table 15. Hypertensive Heart Disease Drug Market Challenges

Table 16. Hypertensive Heart Disease Drug Market Restraints

Table 17. Global Hypertensive Heart Disease Drug Revenue by Players (2018-2023) & (US\$ Million)

Table 18. Global Hypertensive Heart Disease Drug Market Share by Players (2018-2023)

Table 19. Global Top Hypertensive Heart Disease Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hypertensive Heart Disease Drug as of 2022)

Table 20. Ranking of Global Top Hypertensive Heart Disease Drug Companies by Revenue (US\$ Million) in 2022

Table 21. Global 5 Largest Players Market Share by Hypertensive Heart Disease Drug Revenue (CR5 and HHI) & (2018-2023)

Table 22. Key Players Headquarters and Area Served

Table 23. Key Players Hypertensive Heart Disease Drug Product Solution and Service

Table 24. Date of Enter into Hypertensive Heart Disease Drug Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Hypertensive Heart Disease Drug Market Size by Type (2018-2023) & (US\$ Million)

Table 27. Global Hypertensive Heart Disease Drug Revenue Market Share by Type (2018-2023)

Table 28. Global Hypertensive Heart Disease Drug Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 29. Global Hypertensive Heart Disease Drug Revenue Market Share by Type (2024-2029)

Table 30. Global Hypertensive Heart Disease Drug Market Size by Application (2018-2023) & (US\$ Million)

Table 31. Global Hypertensive Heart Disease Drug Revenue Market Share by Application (2018-2023)

Table 32. Global Hypertensive Heart Disease Drug Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 33. Global Hypertensive Heart Disease Drug Revenue Market Share by Application (2024-2029)

Table 34. North America Hypertensive Heart Disease Drug Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 35. North America Hypertensive Heart Disease Drug Market Size by Country (2018-2023) & (US\$ Million)

Table 36. North America Hypertensive Heart Disease Drug Market Size by Country (2024-2029) & (US\$ Million)

Table 37. Europe Hypertensive Heart Disease Drug Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 38. Europe Hypertensive Heart Disease Drug Market Size by Country (2018-2023) & (US\$ Million)

Table 39. Europe Hypertensive Heart Disease Drug Market Size by Country (2024-2029) & (US\$ Million)

Table 40. Asia-Pacific Hypertensive Heart Disease Drug Market Size Growth Rate by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 41. Asia-Pacific Hypertensive Heart Disease Drug Market Size by Region (2018-2023) & (US\$ Million)

Table 42. Asia-Pacific Hypertensive Heart Disease Drug Market Size by Region (2024-2029) & (US\$ Million)

Table 43. Latin America Hypertensive Heart Disease Drug Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 44. Latin America Hypertensive Heart Disease Drug Market Size by Country (2018-2023) & (US\$ Million)

Table 45. Latin America Hypertensive Heart Disease Drug Market Size by Country (2024-2029) & (US\$ Million)

Table 46. Middle East & Africa Hypertensive Heart Disease Drug Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 47. Middle East & Africa Hypertensive Heart Disease Drug Market Size by Country (2018-2023) & (US\$ Million)

Table 48. Middle East & Africa Hypertensive Heart Disease Drug Market Size by Country (2024-2029) & (US\$ Million)

Table 49. Abbott Laboratories Company Detail

Table 50. Abbott Laboratories Business Overview

Table 51. Abbott Laboratories Hypertensive Heart Disease Drug Product

Table 52. Abbott Laboratories Revenue in Hypertensive Heart Disease Drug Business (2018-2023) & (US\$ Million)

Table 53. Abbott Laboratories Recent Development

Table 54. AstraZeneca PLC Company Detail

Table 55. AstraZeneca PLC Business Overview

Table 56. AstraZeneca PLC Hypertensive Heart Disease Drug Product

Table 57. AstraZeneca PLC Revenue in Hypertensive Heart Disease Drug Business (2018-2023) & (US\$ Million)

Table 58. AstraZeneca PLC Recent Development

Table 59. Actelion Pharmaceuticals Ltd. Company Detail

Table 60. Actelion Pharmaceuticals Ltd. Business Overview

Table 61. Actelion Pharmaceuticals Ltd. Hypertensive Heart Disease Drug Product

Table 62. Actelion Pharmaceuticals Ltd. Revenue in Hypertensive Heart Disease Drug Business (2018-2023) & (US\$ Million)

Table 63. Actelion Pharmaceuticals Ltd. Recent Development

Table 64. Boehringer Ingelheim International GmbH Company Detail

Table 65. Boehringer Ingelheim International GmbH Business Overview

Table 66. Boehringer Ingelheim International GmbH Hypertensive Heart Disease Drug Product

Table 67. Boehringer Ingelheim International GmbH Revenue in Hypertensive Heart Disease Drug Business (2018-2023) & (US\$ Million)

Table 68. Boehringer Ingelheim International GmbH Recent Development

Table 69. Bayer AG Company Detail

Table 70. Bayer AG Business Overview

Table 71. Bayer AG Hypertensive Heart Disease Drug Product

Table 72. Bayer AG Revenue in Hypertensive Heart Disease Drug Business

(2018-2023) & (US\$ Million)

Table 73. Bayer AG Recent Development

Table 74. Eiger Biopharmaceuticals, Inc. Company Detail

Table 75. Eiger Biopharmaceuticals, Inc. Business Overview

Table 76. Eiger Biopharmaceuticals, Inc. Hypertensive Heart Disease Drug Product

Table 77. Eiger Biopharmaceuticals, Inc. Revenue in Hypertensive Heart Disease Drug Business (2018-2023) & (US\$ Million)

Table 78. Eiger Biopharmaceuticals, Inc. Recent Development

Table 79. Daiichi Sankyo Co., Ltd. Company Detail

Table 80. Daiichi Sankyo Co., Ltd. Business Overview

Table 81. Daiichi Sankyo Co., Ltd. Hypertensive Heart Disease Drug Product

Table 82. Daiichi Sankyo Co., Ltd. Revenue in Hypertensive Heart Disease Drug Business (2018-2023) & (US\$ Million)

Table 83. Daiichi Sankyo Co., Ltd. Recent Development

Table 84. Gilead Sciences, Inc. Company Detail

Table 85. Gilead Sciences, Inc. Business Overview

Table 86. Gilead Sciences, Inc. Hypertensive Heart Disease Drug Product

Table 87. Gilead Sciences, Inc. Revenue in Hypertensive Heart Disease Drug Business (2018-2023) & (US\$ Million)

Table 88. Gilead Sciences, Inc. Recent Development

Table 89. GlaxoSmithKline PLC Company Detail

Table 90. GlaxoSmithKline PLC Business Overview

Table 91. GlaxoSmithKline PLC Hypertensive Heart Disease Drug Product

Table 92. GlaxoSmithKline PLC Revenue in Hypertensive Heart Disease Drug Business (2018-2023) & (US\$ Million)

Table 93. GlaxoSmithKline PLC Recent Development

Table 94. F. Hoffmann-La Roche Ltd. Company Detail

Table 95. F. Hoffmann-La Roche Ltd. Business Overview

Table 96. F. Hoffmann-La Roche Ltd. Hypertensive Heart Disease Drug Product

Table 97. F. Hoffmann-La Roche Ltd. Revenue in Hypertensive Heart Disease Drug Business (2018-2023) & (US\$ Million)

Table 98. F. Hoffmann-La Roche Ltd. Recent Development

Table 99. Johnson & Johnson Services, Inc. Company Detail

Table 100. Johnson & Johnson Services, Inc. Business Overview

Table 101. Johnson & Johnson Services, Inc. Hypertensive Heart Disease Drug Product

Table 102. Johnson & Johnson Services, Inc. Revenue in Hypertensive Heart Disease Drug Business (2018-2023) & (US\$ Million)

Table 103. Johnson & Johnson Services, Inc. Recent Development

Table 104. Lupin Pharmaceuticals, 13. Merck KGaA Company Detail

- Table 105. Lupin Pharmaceuticals, 13. Merck KGaA Business Overview
- Table 106. Lupin Pharmaceuticals, 13. Merck KGaA Hypertensive Heart Disease Drug Product
- Table 107. Lupin Pharmaceuticals, 13. Merck KGaA Revenue in Hypertensive Heart Disease Drug Business (2018-2023) & (US\$ Million)
- Table 108. Lupin Pharmaceuticals, 13. Merck KGaA Recent Development
- Table 109. Novartis AG Company Detail
- Table 110. Novartis AG Business Overview
- Table 111. Novartis AG Hypertensive Heart Disease Drug Product
- Table 112. Novartis AG Revenue in Hypertensive Heart Disease Drug Business (2018-2023) & (US\$ Million)
- Table 113. Novartis AG Recent Development
- Table 114. Pfizer Inc. Company Detail
- Table 115. Pfizer Inc. Business Overview
- Table 116. Pfizer Inc. Hypertensive Heart Disease Drug Product
- Table 117. Pfizer Inc. Revenue in Hypertensive Heart Disease Drug Business (2018-2023) & (US\$ Million)
- Table 118. Pfizer Inc. Recent Development
- Table 119. Sanofi SA Company Detail
- Table 120. Sanofi SA Business Overview
- Table 121. Sanofi SA Hypertensive Heart Disease Drug Product
- Table 122. Sanofi SA Revenue in Hypertensive Heart Disease Drug Business (2018-2023) & (US\$ Million)
- Table 123. Sanofi SA Recent Development
- Table 124. Sun Pharmaceutical Industries Ltd. Company Detail
- Table 125. Sun Pharmaceutical Industries Ltd. Business Overview
- Table 126. Sun Pharmaceutical Industries Ltd. Hypertensive Heart Disease Drug Product
- Table 127. Sun Pharmaceutical Industries Ltd. Revenue in Hypertensive Heart Disease Drug Business (2018-2023) & (US\$ Million)
- Table 128. Sun Pharmaceutical Industries Ltd. Recent Development
- Table 129. Takeda Pharmaceutical Co. Ltd. Company Detail
- Table 130. Takeda Pharmaceutical Co. Ltd. Business Overview
- Table 131. Takeda Pharmaceutical Co. Ltd. Hypertensive Heart Disease Drug Product
- Table 132. Takeda Pharmaceutical Co. Ltd. Revenue in Hypertensive Heart Disease Drug Business (2018-2023) & (US\$ Million)
- Table 133. Takeda Pharmaceutical Co. Ltd. Recent Development
- Table 134. United Therapeutics Corp. Company Detail
- Table 135. United Therapeutics Corp. Business Overview

Table 136. United Therapeutics Corp. Hypertensive Heart Disease Drug Product

Table 137. United Therapeutics Corp. Revenue in Hypertensive Heart Disease Drug Business (2018-2023) & (US\$ Million)

Table 138. United Therapeutics Corp. Recent Development

Table 139. Northern Therapeutics Inc. Company Detail

Table 140. Northern Therapeutics Inc. Business Overview

Table 141. Northern Therapeutics Inc. Hypertensive Heart Disease Drug Product

Table 142. Northern Therapeutics Inc. Revenue in Hypertensive Heart Disease Drug Business (2018-2023) & (US\$ Million)

Table 143. Northern Therapeutics Inc. Recent Development

Table 144. Research Programs/Design for This Report

Table 145. Key Data Information from Secondary Sources

Table 146. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Hypertensive Heart Disease Drug Market Size Comparison by Type (2023-2029) & (US\$ Million)

Figure 2. Global Hypertensive Heart Disease Drug Market Share by Type: 2022 VS 2029

Figure 3. Calcium Channel Blockers Features

Figure 4. Diuretics Features

Figure 5. Beta Blockers Features

Figure 6. ACE Inhibitors Features

Figure 7. Potassium Replacements Features

Figure 8. Global Hypertensive Heart Disease Drug Market Size Comparison by Application (2023-2029) & (US\$ Million)

Figure 9. Global Hypertensive Heart Disease Drug Market Share by Application: 2022 VS 2029

Figure 10. Hospital Pharmacies Case Studies

Figure 11. Retail Pharmacies Case Studies

Figure 12. Online Pharmacies Case Studies

Figure 13. Hypertensive Heart Disease Drug Report Years Considered

Figure 14. Global Hypertensive Heart Disease Drug Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 15. Global Hypertensive Heart Disease Drug Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 16. Global Hypertensive Heart Disease Drug Market Share by Region: 2022 VS 2029

Figure 17. Global Hypertensive Heart Disease Drug Market Share by Players in 2022

Figure 18. Global Top Hypertensive Heart Disease Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hypertensive Heart Disease Drug as of 2022)

Figure 19. The Top 10 and 5 Players Market Share by Hypertensive Heart Disease Drug Revenue in 2022

Figure 20. North America Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 21. North America Hypertensive Heart Disease Drug Market Share by Country (2018-2029)

Figure 22. United States Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 23. Canada Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. Europe Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 25. Europe Hypertensive Heart Disease Drug Market Share by Country (2018-2029)

Figure 26. Germany Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 27. France Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. U.K. Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. Italy Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. Russia Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Nordic Countries Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Asia-Pacific Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. Asia-Pacific Hypertensive Heart Disease Drug Market Share by Region (2018-2029)

Figure 34. China Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. Japan Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. South Korea Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. Southeast Asia Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 38. India Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 39. Australia Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 40. Latin America Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 41. Latin America Hypertensive Heart Disease Drug Market Share by Country (2018-2029)

Figure 42. Mexico Hypertensive Heart Disease Drug Market Size YoY Growth

(2018-2029) & (US\$ Million)

Figure 43. Brazil Hypertensive Heart Disease Drug Market Size YoY Growth

(2018-2029) & (US\$ Million)

Figure 44. Middle East & Africa Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. Middle East & Africa Hypertensive Heart Disease Drug Market Share by Country (2018-2029)

Figure 46. Turkey Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 47. Saudi Arabia Hypertensive Heart Disease Drug Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 48. Abbott Laboratories Revenue Growth Rate in Hypertensive Heart Disease Drug Business (2018-2023)

Figure 49. AstraZeneca PLC Revenue Growth Rate in Hypertensive Heart Disease Drug Business (2018-2023)

Figure 50. Actelion Pharmaceuticals Ltd. Revenue Growth Rate in Hypertensive Heart Disease Drug Business (2018-2023)

Figure 51. Boehringer Ingelheim International GmbH Revenue Growth Rate in Hypertensive Heart Disease Drug Business (2018-2023)

Figure 52. Bayer AG Revenue Growth Rate in Hypertensive Heart Disease Drug Business (2018-2023)

Figure 53. Eiger Biopharmaceuticals, Inc. Revenue Growth Rate in Hypertensive Heart Disease Drug Business (2018-2023)

Figure 54. Daiichi Sankyo Co., Ltd. Revenue Growth Rate in Hypertensive Heart Disease Drug Business (2018-2023)

Figure 55. Gilead Sciences, Inc. Revenue Growth Rate in Hypertensive Heart Disease Drug Business (2018-2023)

Figure 56. GlaxoSmithKline PLC Revenue Growth Rate in Hypertensive Heart Disease Drug Business (2018-2023)

Figure 57. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Hypertensive Heart Disease Drug Business (2018-2023)

Figure 58. Johnson & Johnson Services, Inc. Revenue Growth Rate in Hypertensive Heart Disease Drug Business (2018-2023)

Figure 59. Lupin Pharmaceuticals, 13. Merck KGaA Revenue Growth Rate in Hypertensive Heart Disease Drug Business (2018-2023)

Figure 60. Novartis AG Revenue Growth Rate in Hypertensive Heart Disease Drug Business (2018-2023)

Figure 61. Pfizer Inc. Revenue Growth Rate in Hypertensive Heart Disease Drug Business (2018-2023)

Figure 62. Sanofi SA Revenue Growth Rate in Hypertensive Heart Disease Drug Business (2018-2023)

Figure 63. Sun Pharmaceutical Industries Ltd. Revenue Growth Rate in Hypertensive Heart Disease Drug Business (2018-2023)

Figure 64. Takeda Pharmaceutical Co. Ltd. Revenue Growth Rate in Hypertensive Heart Disease Drug Business (2018-2023)

Figure 65. United Therapeutics Corp. Revenue Growth Rate in Hypertensive Heart Disease Drug Business (2018-2023)

Figure 66. Northern Therapeutics Inc. Revenue Growth Rate in Hypertensive Heart Disease Drug Business (2018-2023)

Figure 67. Bottom-up and Top-down Approaches for This Report

Figure 68. Data Triangulation

Figure 69. Key Executives Interviewed

I would like to order

Product name: Global Hypertensive Heart Disease Drug Market Research Report 2023

Product link: <https://marketpublishers.com/r/G69735A54CC9EN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G69735A54CC9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970